Global benefit-risk assessment of antidepressants: Venlafaxine XR and fluoxetine

Journal of Psychiatric Research

Volumn 36, Issue 3, 2002, Pages 111-118

  Entsuah, Richard ^a   Gorman, Jack M ^b  

^a PFIZER INC   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Fluoxetine; Global benefit risk; Remission; Response; Venlafaxine XR

Indexed keywords

FLUOXETINE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; INSOMNIA; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; RATING SCALE; REMISSION; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SOMNOLENCE; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0036120915     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(01)00055-3     Document Type: Article

References (23)

1. Basic aspects of risk-benefit analysis
2. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia
3. A new proposal for benefit-less-risk analysis in clinical trials
4. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials
5. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia
6. Designs for phase II trials allowing for a trade-off between response and toxicity
7. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients
8. High-dose chemotherapy in the adjuvant treatment of breast cancer: Benefit/risk analysis
9. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression
10. Cardiovascular effects of therapeutic doses of tricyclic antidepressants
11. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered
12. Cardiovascular effects of tricyclic antidepressants
13. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia
14. The assessment of anxiety states by rating
15. The role of serotonin in depression
16. Threats to the validity of clinical trials employing enrichment strategies for sample selection
17. Clinical global impressions
18. Somatic therapy for major depressive disorder: Selection of an antidepressant
19. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
20. Measuring the functional impact of fibromyalgia
21. A scale for assessing the severity of diseases and adverse drug reactions. Application to drug benefit and risk
22. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors